Epstein-Barr Virus (EBV) Hyperimmune Globulin Isolated from Donors with High Gp350 Antibody Titers Protect Humanized Mice from Challenge with EBV

Overview

Journal Virology

Specialty Microbiology

Date 2021 Jun 25

PMID 34171765

Citations 6

Authors

JungHyun Kim

Wei Bu

Sohtaro Mine

Zeshan Tariq

Hanh Nguyen

Yanmei Wang

Cynthia Tolman

James Mond

Jeffrey I Cohen

Affiliations

Soon will be listed here.

Abstract

Primary infection with Epstein-Barr virus (EBV) is associated with post-transplant lymphoproliferative disease and severe disease in patients with X-linked lymphoproliferative disease; no therapies are approved to prevent EBV infection in these patients. Hyperimmune globulin has been used to prevent some virus infections in immunocompromised persons. Here, we identified plasma donors with high titers of EBV gp350 and EBV B cell neutralizing antibodies. Pooled IgG isolated from these donors was compared to intravenous immunoglobulin (IVIG) for its ability to reduce viral load in the blood in humanized mice challenged with EBV. Mice that received EBV hyperimmune globulin had significantly reduced EBV DNA copy numbers compared to animals that received saline control; however, while animals that received EBV hyperimmune globulin had lower EBV DNA copies than those that received IVIG, the difference was not significant. Thus, while EBV hyperimmune globulin reduced viral load compared to IVIG, the effect was modest.

Citing Articles

Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice.

Escalante G, Reidel I, Mutsvunguma L, Cua S, Tello B, Rodriguez E Front Immunol. 2024; 15():1445209.

PMID: 39346922 PMC: 11427267. DOI: 10.3389/fimmu.2024.1445209.

Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells.

Bu W, Kumar A, Board N, Kim J, Dowdell K, Zhang S Immunity. 2024; 57(3):559-573.e6.

PMID: 38479361 PMC: 11000673. DOI: 10.1016/j.immuni.2024.02.008.

Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.

Chen W, Kim J, Bu W, Board N, Tsybovsky Y, Wang Y Immunity. 2022; 55(11):2135-2148.e6.

PMID: 36306784 PMC: 9815946. DOI: 10.1016/j.immuni.2022.10.003.

Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge.

Malhi H, Homad L, Wan Y, Poudel B, Fiala B, Borst A Cell Rep Med. 2022; 3(6):100658.

PMID: 35705092 PMC: 9245003. DOI: 10.1016/j.xcrm.2022.100658.

Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.

Escalante G, Mutsvunguma L, Muniraju M, Rodriguez E, Ogembo J Front Immunol. 2022; 13:867918.

PMID: 35493498 PMC: 9047024. DOI: 10.3389/fimmu.2022.867918.

References

Orange J, Hossny E, Weiler C, Ballow M, Berger M, Bonilla F . Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006; 117(4 Suppl):S525-53. DOI: 10.1016/j.jaci.2006.01.015. View

Wu L, Hutt-Fletcher L . Point mutations in EBV gH that abrogate or differentially affect B cell and epithelial cell fusion. Virology. 2007; 363(1):148-55. PMC: 1965494. DOI: 10.1016/j.virol.2007.01.025. View

Ogembo J, Kannan L, Ghiran I, Nicholson-Weller A, Finberg R, Tsokos G . Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor. Cell Rep. 2013; 3(2):371-85. PMC: 3633082. DOI: 10.1016/j.celrep.2013.01.023. View

Delecluse H, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W . Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A. 1998; 95(14):8245-50. PMC: 20961. DOI: 10.1073/pnas.95.14.8245. View

Humar A, Hebert D, Davies H, Humar A, Stephens D, ODoherty B . A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation. 2006; 81(6):856-61. DOI: 10.1097/01.tp.0000202724.07714.a2. View

Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H . A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis. 2008; 198(5):673-82. DOI: 10.1086/590502. View

Seemayer T, Gross T, Egeler R, Pirruccello S, Davis J, Kelly C . X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995; 38(4):471-8. DOI: 10.1203/00006450-199510000-00001. View

Bu W, Joyce M, Nguyen H, Banh D, Aguilar F, Tariq Z . Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. Immunity. 2019; 50(5):1305-1316.e6. PMC: 6660903. DOI: 10.1016/j.immuni.2019.03.010. View

San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch H, Meylan P . Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect. 2014; 20 Suppl 7:109-18. DOI: 10.1111/1469-0691.12534. View

10.

Cho Y, Gordadze A, Ling P, Wang F . Evolution of two types of rhesus lymphocryptovirus similar to type 1 and type 2 Epstein-Barr virus. J Virol. 1999; 73(11):9206-12. PMC: 112954. DOI: 10.1128/JVI.73.11.9206-9212.1999. View

11.

Neuhierl B, Feederle R, Hammerschmidt W, Delecluse H . Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci U S A. 2002; 99(23):15036-41. PMC: 137540. DOI: 10.1073/pnas.232381299. View

12.

Nemerow G, Mold C, Schwend V, Tollefson V, Cooper N . Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987; 61(5):1416-20. PMC: 254117. DOI: 10.1128/JVI.61.5.1416-1420.1987. View

13.

Cohen J . Primary Immunodeficiencies Associated with EBV Disease. Curr Top Microbiol Immunol. 2015; 390(Pt 1):241-65. PMC: 6349415. DOI: 10.1007/978-3-319-22822-8_10. View

14.

Janz A, Oezel M, Kurzeder C, Mautner J, Pich D, Kost M . Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol. 2000; 74(21):10142-52. PMC: 102053. DOI: 10.1128/jvi.74.21.10142-10152.2000. View

15.

Haque T, Johannessen I, Dombagoda D, Sengupta C, Burns D, Bird P . A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. J Infect Dis. 2006; 194(5):584-7. DOI: 10.1086/505912. View

16.

Herrman M, Muhe J, Quink C, Wang F . Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques. J Virol. 2015; 90(3):1222-30. PMC: 4719629. DOI: 10.1128/JVI.02531-15. View

17.

Ahearn J, Hayward S, HICKEY J, Fearon D . Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor. Proc Natl Acad Sci U S A. 1988; 85(23):9307-11. PMC: 282728. DOI: 10.1073/pnas.85.23.9307. View

18.

Sokal E, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A . Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2008; 196(12):1749-53. DOI: 10.1086/523813. View

19.

Strowig T, Gurer C, Ploss A, Liu Y, Arrey F, Sashihara J . Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med. 2009; 206(6):1423-34. PMC: 2715061. DOI: 10.1084/jem.20081720. View

20.

Mutsvunguma L, Rodriguez E, Escalante G, Muniraju M, Williams J, Warden C . Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes. Virology. 2019; 536():1-15. PMC: 6733660. DOI: 10.1016/j.virol.2019.07.026. View